Following the completion of the site initiation visit at Weill Cornell Medical Center in New York for the Phase 2 clinical trial of CYP-001 in High-Risk acute Graft versus Host Disease (HR-aGvHD), Dr Kilian Kelly sat down with Ausbiz to explain what this means.